1. What is the projected Compound Annual Growth Rate (CAGR) of the U.S. Influenza Vaccine Market?
The projected CAGR is approximately 9.3%.
U.S. Influenza Vaccine MarketU.S. Influenza Vaccine Market 2025-2033 Analysis: Trends, Competitor Dynamics, and Growth Opportunities
U.S. Influenza Vaccine Market by Type (Inactivated, Live Attenuated), by Valency (Quadrivalent, Trivalent), by Age Group (Pediatric, Adults), by Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others), by Forecast 2025-2033
Base Year: 2024
120 Pages
U.S. Influenza Vaccine Market 2025-2033 Analysis: Trends, Competitor Dynamics, and Growth Opportunities
U.S. Influenza Vaccine Market 2025-2033 Analysis: Trends, Competitor Dynamics, and Growth Opportunities
Key Insights
The U.S. Influenza Vaccine Market size was valued at USD 3.77 USD Billion in 2023 and is projected to reach USD 7.03 USD Billion by 2032, exhibiting a CAGR of 9.3 % during the forecast period. The US influenza vaccination market holds a primary position in the battle against seasonal flu and its complex intricacies. The vaccine is called a trivalent or quadrivalent that handles several influenza human strains. Vaccinations are given yearly to every age group, especially to kids, the elderly, and people who have chronic ailments. The market consists of inactivated influenza vaccines (IIVs), live attenuated influenza vaccines (LAIVs), and recombinant influenza vaccines (RIVs). Reciprocal innovations like cellular and recombinant DNA technologies have resulted in more precise and efficient ways of making vaccines. The effect of universal vaccination will imply the non-occurrence of flu, to a lesser extent, and healthcare expenses, which will certainly improve the state of public health. Key benefits have a double-edged sword: the status of the community is stronger due to the enforcement of herd immunity and the decreased level of transmission, as well as the protection of those who are at the highest health risk.
U.S. Influenza Vaccine Trends
- Growing burden of influenza and government emphasis on preventive vaccination.
- Technological advancements in vaccine development, leading to improved efficacy and safety.
- Increasing adoption of quadrivalent vaccines due to broader protection against different strains.
Driving Forces: What's Propelling the U.S. Influenza Vaccine Market
- Rising prevalence of influenza and associated complications.
- Government initiatives to promote vaccination and control influenza outbreaks.
- Improved vaccine efficacy and safety.
- Expansion of vaccination programs to include high-risk groups.
Challenges and Restraints in U.S. Influenza Vaccine Market
- Vaccine Hesitancy and Misinformation: Vaccine reluctance and anti-vaccination propaganda continue to hinder vaccination rates.
- Viral Evolution and Strain Variability: Influenza viruses constantly mutate, leading to mismatches between vaccine strains and circulating strains.
- Cost and Reimbursement Barriers: The high cost of influenza vaccines and limited coverage by insurance plans can be a barrier to vaccination.
- Production and Supply Chain Challenges: Scaling up vaccine production and ensuring timely distribution can be challenging, especially during a pandemic.
Emerging Trends in U.S. Influenza Vaccine
- Development of mRNA-based vaccines for influenza, offering potential for improved efficacy.
- Personalized vaccines tailored to individual immune responses.
- Non-invasive vaccine delivery methods, such as nasal sprays.
Growth Catalysts in U.S. Influenza Vaccine Industry
- Government funding for research and development of influenza vaccines, enabling the development of more effective and targeted vaccines.
- Public health campaigns to raise awareness about influenza and vaccination, increasing public demand and uptake of influenza vaccines.
- Technological advancements in vaccine manufacturing and distribution, such as improved production methods and innovative delivery systems, enhancing vaccine availability and efficiency.
- Growing awareness of the health and economic benefits of influenza vaccination, leading to increased demand from both individuals and healthcare providers.
- Emergence of new influenza strains and outbreaks, emphasizing the need for regular vaccination to prevent infection and reduce disease severity.
Market Segmentation: U.S. Influenza Vaccine Analysis
By Type:
- Inactivated
- Live Attenuated
By Valency:
- Quadrivalent
- Trivalent
By Age Group:
- Pediatric
- Adults
By Distribution Channel:
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
Leading Players in the U.S. Influenza Vaccine Market
- GlaxoSmithKline plc (U.K.)
- Sanofi (France)
- AstraZeneca (U.K.)
- BIKEN Co., Ltd. (Japan)
- Abbott (U.S.)
- Viatris Inc. (U.S.)
Significant developments in U.S. Influenza Vaccine Sector
- December 2022: Pfizer and BioNTech received the FDA fast-track designation for mRNA-based single-dose vaccine against influenza and COVID-19.
- July 2022: Sanofi flu vaccine received the U.S. FDA license and approval for Flublok quadrivalent vaccine for 2022-2023 influenza season.
- October 2021: CSL Sequris received the U.S. FDA approval for Flucelvax Quadrivalent, a cell-based influenza vaccine indicated for children as young as six months old.
Comprehensive Coverage U.S. Influenza Vaccine Market Report
- Market Overview: Provides a high-level summary of the industry, including market size, growth drivers, and challenges.
- Market Analysis by Segment: Offers a detailed segmentation of the market based on factors such as vaccine type, target population, and distribution channel.
- Market Dynamics: Explores the key factors influencing market growth, including regulatory policies, technological advancements, and competitive dynamics.
- Competitive Landscape: Provides an overview of the major players in the industry, their market share, and their strategies.
- Industry Trends and Forecast: Discusses emerging trends in the market, including the adoption of new technologies and the impact of infectious disease outbreaks.
- Key Market Insights: Presents valuable insights into the future direction of the industry, including growth opportunities and potential risks.
Regional Insight
- North America: High vaccination rates due to government mandates and public health awareness, leading to declining influenza incidence.
- Europe: Similar to North America, with high vaccination rates and government support for influenza control programs.
- Asia Pacific: Rapidly expanding population and increasing demand for vaccines, but challenges with vaccination coverage and distribution in some regions.
- Latin America: Improving vaccination rates, but gaps remain in access and affordability of vaccines.
- Middle East and Africa: Lower vaccination rates compared to other regions, due to limited healthcare infrastructure and logistical challenges.
DROCT
- Company Profiles
- SWOT Analysis
- Product Analysis
- Financial Analysis
- Regulatory Landscape
Pricing Analysis
- Price Analysis
- Product Differentiation
- Pricing Strategies
Import And Export Analysis
- Import and Export Data
- Trade Regulations
- Market Trends
Segmentation
- Sub-Market Analysis
- Regional Segmentation
- End-User Segmentation
Patent/Trademark Analysis
- Patent Database
- Trademark Database
- Intellectual Property Landscape
U.S. Influenza Vaccine Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 9.3% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Prevalence of Brain Cancer Cases to Propel Market Growth
- 3.3. Market Restrains
- 3.3.1. Longer Manufacturing Timeline for Vaccines Coupled with Stringent Approval Guidelines to Impede the Market Growth
- 3.4. Market Trends
- 3.4.1. Increasing Number of Hospitals and ASCs Identified as Significant Market Trend
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. U.S. Influenza Vaccine Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Type
- 5.1.1. Inactivated
- 5.1.2. Live Attenuated
- 5.2. Market Analysis, Insights and Forecast - by Valency
- 5.2.1. Quadrivalent
- 5.2.2. Trivalent
- 5.3. Market Analysis, Insights and Forecast - by Age Group
- 5.3.1. Pediatric
- 5.3.2. Adults
- 5.4. Market Analysis, Insights and Forecast - by Distribution Channel
- 5.4.1. Hospital & Retail Pharmacies
- 5.4.2. Government Suppliers
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - by Region
- 5.5.1.
- 5.1. Market Analysis, Insights and Forecast - by Type
- 6. Northeast U.S. Influenza Vaccine Market Analysis, Insights and Forecast, 2019-2031
- 7. Southeast U.S. Influenza Vaccine Market Analysis, Insights and Forecast, 2019-2031
- 8. Midwest U.S. Influenza Vaccine Market Analysis, Insights and Forecast, 2019-2031
- 9. Southwest U.S. Influenza Vaccine Market Analysis, Insights and Forecast, 2019-2031
- 10. West U.S. Influenza Vaccine Market Analysis, Insights and Forecast, 2019-2031
- 11. Competitive Analysis
- 11.1. Market Share Analysis 2024
- 11.2. Company Profiles
- 11.2.1 GlaxoSmithKline plc (U.K.)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Sanofi (France)
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 AstraZeneca (U.K.)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 CSL Limited (Australia)
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 BIKEN Co. Ltd. (Japan)
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Abbott (U.S.)
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Viatris Inc. (U.S.)
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.1 GlaxoSmithKline plc (U.K.)
List of Figures
- Figure 1: U.S. Influenza Vaccine Market Revenue Breakdown (USD Billion, %) by Product 2024 & 2032
- Figure 2: U.S. Influenza Vaccine Market Share (%) by Company 2024
List of Tables
- Table 1: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Region 2019 & 2032
- Table 2: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Region 2019 & 2032
- Table 3: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Type 2019 & 2032
- Table 4: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Type 2019 & 2032
- Table 5: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Valency 2019 & 2032
- Table 6: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Valency 2019 & 2032
- Table 7: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Age Group 2019 & 2032
- Table 8: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Age Group 2019 & 2032
- Table 9: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Distribution Channel 2019 & 2032
- Table 10: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Distribution Channel 2019 & 2032
- Table 11: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Region 2019 & 2032
- Table 12: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Region 2019 & 2032
- Table 13: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Country 2019 & 2032
- Table 14: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Country 2019 & 2032
- Table 15: Northeast U.S. Influenza Vaccine Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 16: Northeast U.S. Influenza Vaccine Market Volume (K Tons) Forecast, by Application 2019 & 2032
- Table 17: Southeast U.S. Influenza Vaccine Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 18: Southeast U.S. Influenza Vaccine Market Volume (K Tons) Forecast, by Application 2019 & 2032
- Table 19: Midwest U.S. Influenza Vaccine Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 20: Midwest U.S. Influenza Vaccine Market Volume (K Tons) Forecast, by Application 2019 & 2032
- Table 21: Southwest U.S. Influenza Vaccine Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 22: Southwest U.S. Influenza Vaccine Market Volume (K Tons) Forecast, by Application 2019 & 2032
- Table 23: West U.S. Influenza Vaccine Market Revenue (USD Billion) Forecast, by Application 2019 & 2032
- Table 24: West U.S. Influenza Vaccine Market Volume (K Tons) Forecast, by Application 2019 & 2032
- Table 25: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Type 2019 & 2032
- Table 26: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Type 2019 & 2032
- Table 27: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Valency 2019 & 2032
- Table 28: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Valency 2019 & 2032
- Table 29: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Age Group 2019 & 2032
- Table 30: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Age Group 2019 & 2032
- Table 31: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Distribution Channel 2019 & 2032
- Table 32: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Distribution Channel 2019 & 2032
- Table 33: U.S. Influenza Vaccine Market Revenue USD Billion Forecast, by Country 2019 & 2032
- Table 34: U.S. Influenza Vaccine Market Volume K Tons Forecast, by Country 2019 & 2032
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
2. Which companies are prominent players in the U.S. Influenza Vaccine Market?
Key companies in the market include GlaxoSmithKline plc (U.K.), Sanofi (France), AstraZeneca (U.K.), CSL Limited (Australia), BIKEN Co., Ltd. (Japan), Abbott (U.S.), Viatris Inc. (U.S.).
3. What are the main segments of the U.S. Influenza Vaccine Market?
The market segments include Type, Valency, Age Group, Distribution Channel.
4. Can you provide details about the market size?
The market size is estimated to be USD 3.77 USD Billion as of 2022.
5. What are some drivers contributing to market growth?
Rising Prevalence of Brain Cancer Cases to Propel Market Growth.
6. What are the notable trends driving market growth?
Increasing Number of Hospitals and ASCs Identified as Significant Market Trend.
7. Are there any restraints impacting market growth?
Longer Manufacturing Timeline for Vaccines Coupled with Stringent Approval Guidelines to Impede the Market Growth.
8. Can you provide examples of recent developments in the market?
December 2022- Pfizer and BioNTech received the FDA fast-track designation for mRNA-based single-dose vaccine against influenza and COVID-19.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2850, USD 3850, and USD 4850 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in USD Billion and volume, measured in K Tons.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "U.S. Influenza Vaccine Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the U.S. Influenza Vaccine Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the U.S. Influenza Vaccine Market?
To stay informed about further developments, trends, and reports in the U.S. Influenza Vaccine Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.